FDA tells Supreme Court to pass on Vanda's fast-track status fight

The FDA is urging the US Supreme Court not to take up a case over its denial of fast-track status for Vanda Pharmaceuticals’ experimental drug tradipitant. The case involves the FDA’s fast-track program, which is ...